STK11 and lung carcinoma: A study using CRISPR/Cas9 technology to compare the effects of STK11 and PTEN on lung cancer development confirmed that mutations in STK11, but not PTEN, promote the progression of KrasG12D mutation lung adenocarcinomas [39].